Blinding, Expectancy, and the Active Placebo Paradox in MDMA Research.
Psychopharmacology (Berl) June 13, 2026 DOI: 10.1007/s00213-026-07108-6 (opens in new tab) via PubMed
Summary
AI-generated from the abstractThe text examines how blinding and expectancy effects complicate placebo-controlled trials of MDMA, introducing the concept of an 'active placebo paradox.' It argues that the strong subjective effects of MDMA make true blinding nearly impossible, which can inflate treatment effects and undermine causal inference. The authors suggest that expectancy and unblinding may account for a substantial portion of the therapeutic outcomes reported in MDMA research, raising questions about the validity of findings from such trials.
Study at a glance
| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key finding | Argues that the active placebo paradox—where MDMA's strong subjective effects compromise blinding—challenges the validity of standard placebo-controlled trials and requires alternative methodological designs. |
Abstract
Blinding, Expectancy, and the Active Placebo Paradox in MDMA Research.